Solu Therapeutics, a biotechnology company pioneering novel therapies to eliminate disease-driving cells in cancer, ...

Autobahn expects topline data from the ongoing Phase II AMPLIFY-BD trial in adjunctive bipolar depression in the second ...

Autobahn Therapeutics, Inc., a biotechnology company developing restorative treatments for people affected by neuropsychiatric disorders, today announced that the U.S. Food and Drug Administration ...

The FDA has granted Fast Track designation to elunetirom as an adjunctive treatment for adults with bipolar I or bipolar II depression.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

FDA fast track status was supported by two monotherapy responses in MSI-H colorectal cancer, including one complete response ...

Please provide your email address to receive an email when new articles are posted on . VTx-002 targets proteins that play a significant role in neurodegenerative disease. Enrollment in and ...

MNV-201, a mitochondrial cell therapy, received FDA fast track designation for myelodysplastic syndrome, highlighting its potential to address mitochondrial dysfunction in this serious blood disorder.

ADCE-D01 targets the uPARAP protein in sarcomas, delivering medication directly to cancer cells, showing promise in early studies. The ADCElerate1 trial evaluates ADCE-D01's safety, tolerability, ...

The Dermatology Division of the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to sonelokimab (SLK) in moderate-to-severe palmoplantar pustulosis (PPP) supported by ...